Genital herpes: current understanding of diagnosis and treatment
Bayramova G.R., Andreev A.O., Mezhevitinova E.A., Abakarova P.R., Babich V.D.
Genital herpes is currently associated with a global prevalence and increasing incidence. Every tenth person of reproductive age is infected with herpes simplex virus type 2. However, the actual prevalence of the virus may be 5–10 times higher, due to the asymptomatic nature of the disease, making it challenging to accurately determine the statistical prevalence. In addition, genital herpes is associated with the risk of developing neurological complications and co-infections. Recent published studies demonstrate an increased risk of human papillomavirus infection and bacterial vaginosis in patients with genital herpes. Women with compromised immune function deserve special attention due to the potential for severe disease. Currently, resistance to acyclic nucleosides and high recurrence rates of genital herpes are observed in a number of clinical cases. The results of the study on the use of combination therapy with dietary supplements containing restriction enzymes (Radaleya) in patients with genital herpes show high clinical efficacy (63.3% of patients had no symptoms as early as the 2nd day of treatment) and a low frequency of repeated episodes (3.3%) during 6–12 months of follow-up.
Conclusion: Taking into account the data from the world literature indicating the existing problem of resistance to first-line drugs for genital herpes and the high risk of recurrence of the disease after treatment, it is advisable to search for new approaches to the choice of therapy. In this regard, the use of the Radaleya dietary supplement, which has a multidirectional antiviral mechanism, in the complex treatment of genital herpes can help to stop the clinical symptoms of the disease, increase the effectiveness of the prescribed treatment, and reduce the likelihood of recurrence of the disease.
Authors’ contributions: Bayramova G.R., Andreev A.O. – search and analysis of the literary sources; Babich V.D., Mezhevitinova E.A. – collecting the data; Bayramova G.R. – scientific supervision, editing the text; Andreev A.O., Babich V.D. – writing the text, developing the design; Bayramova G.R., Abakarova P.R. – examination and treatment of patients.
Conflicts of interest: Authors declare lack of the possible conflicts of interest.
Funding: The study was performed without sponsorship.
For citation: Bayramova G.R., Andreev A.O., Mezhevitinova E.A., Abakarova P.R., Babich V.D.
Genital herpes: current understanding of diagnosis and treatment.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (12): 162-166 (in Russian)
https://dx.doi.org/10.18565/aig.2025.352
Keywords
genital herpes
recurrent course
combination therapy
References
- WHO. Herpes simplex virus. 30 May 2025. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/herpes-simplex-virus
- Looker K.J., Welton N.J., Sabin K.M., Dalal S., Vickerman P., Turner K.M.E. et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect. Dis. 2020; 20(2): 240-9. https://dx.doi.org/10.1016/S1473-3099(19)30470-0
- Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 году. Доступно по: https://cgon.rospotrebnadzor.ru/biznesu/profilaktika-nadzor-uslsugi/profilakticheskie-meropriatiya/gosudarstvennyy-doklad-o-sostoyanii-sanitarno-epidemiologicheskogo-blagopoluchiya-naseleniya-v-rossi/ [Federal Service for Supervision of Consumer Rights Protection and Human Welfare. On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2022. Available at: https://cgon.rospotrebnadzor.ru/biznesu/profilaktika-nadzor-uslsugi/profilakticheskie-meropriatiya/gosudarstvennyy-doklad-o-sostoyanii-sanitarno-epidemiologicheskogo-blagopoluchiya-naseleniya-v-rossi/ (in Russian)].
- Wald A., Corey L. Persistence in the population: epidemiology, transmission. In: Arvin A. et al. (eds). Human Herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press; 2007.
- Patel R., Moran B., Clarke E., Geretti A.M., Lautenschlager S., Green J. et al. 2024 European guidelines for the management of genital herpes. J. Eur. Acad. Dermatol. Venereol. 2025; 39(4): 742-58. https://dx.doi.org/10.1111/jdv.20450
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Аногенитальная герпетическая вирусная инфекция. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Anogenital herpes viral infection. 2024 (in Russian)].
- James C., Harfouche M., Welton N.J., Turner K.M., Abu-Raddad L.J., Gottlieb S.L. et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull. World Health Organ. 2020; 98(5): 315-29. https://dx.doi.org/10.2471/BLT.19.237149
- Zhu S., Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence. 2021; 12(1): 2670-702. https://dx.doi.org/10.1080/21505594.2021.1982373
- Meller N., Levy I., Yinon Y., Kassem R., Baum M. Genital herpes management in pregnancy: knowledge and practices of healthcare providers. Int. J. Gynaecol. Obstet. 2025. https://dx.doi.org/10.1002/ijgo.70480
- Kristensen T.S., Foldager A., Laursen A.S.D., Mikkelsen E.M. Sexually transmitted infections (Chlamydia trachomatis, genital HSV, and HPV) and female fertility: a scoping review. Sex. Reprod. Healthc. 2025; 43: 101067. https://dx.doi.org/10.1016/j.srhc.2025.101067
- Liu C., Guo Y., Wang L., Guo R., Lei D. Association between herpes simplex virus type 2 and high-risk human papillomavirus infections: a population study of the National Health and Nutrition Examination Survey, 2009-2016. J. Infect. Dis. 2025; 231(4): e650-8. https://dx.doi.org/10.1093/infdis/jiaf033
- Asare K., Ngcapu S., Osman F., Mindel A., Naicker N., Khanyile M. et al. Incidence of herpes simplex virus type 2 positivity among women living with human immunodeficiency virus in South Africa. Int. J. STD AIDS. 2024; 35(1): 58-66. https://dx.doi.org/10.1177/09564624231201189
- Esber A., Vicetti Miguel R.D., Cherpes T.L., Klebanoff M.A., Gallo M.F., Turner A.N. Risk of bacterial vaginosis among women with herpes simplex virus type 2 infection: a systematic review and meta-analysis. J. Infect. Dis. 2015; 212(1): 8-17. https://dx.doi.org/10.1093/infdis/jiv017
- Fatahzadeh M., Schwartz R.A. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J. Am. Acad. Dermatol. 2007; 57(5): 737-63; quiz 764-6. https://dx.doi.org/10.1016/j.jaad.2007.06.027
- Libraty D.H., Bocelli L., Fraire A. Herpes simplex virus bronchiolitis in a cannabis user. IDCases. 2013; 1(1): 2-4. https://dx.doi.org/10.1016/j.idcr.2013.11.001
- Bodsworth N., Fife K., Koltun W., Tyring S., Abudalu M., Prichard M., Hamed K. Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. Curr. Med. Res. Opin. 2009; 25(2): 483-7. https://dx.doi.org/10.1185/03007990802664678
- Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T. et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 2004; 350(1): 11-20. https://dx.doi.org/10.1056/NEJMoa035144
- Saiag P., Praindhui D., Chastang C. A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group. J. Antimicrob. Chemother. 1999; 44(4): 525-31. https://dx.doi.org/10.1093/jac/44.4.525
- Mariager T., Terkelsen J.H., Guldbæk J.M., Nielsen M.D., Vestergaard J., Bue M. et al. Distribution of acyclovir in central nervous system compartments: a porcine pharmacokinetic model. Antimicrob. Agents Chemother. 2025; 69(8): e0181124. https://dx.doi.org/10.1128/aac.01811-24
- Келин Л.В., Ефремов А.В. Определение цитотоксичности и противовирусного действия компонентов БАД «Радалея» в отношении коронавируса ОС43 и вируса герпеса. Вестник Сибирского института непрерывного медицинского образования. 2025; 2(8): 43-52. [Kelin L.V., Efremov A.V. Determination of cytotoxicity and antiviral action of the components of the dietary supplement "Radaleya" in relation to coronavirus OS43 and the herpes virus. Bulletin of Siberian Institute of Continuous Medical Education. 2025; 2(8): 43-52 (in Russian)].
Received 03.12.2025
Accepted 09.12.2025
About the Authors
Gyuldana R. Bayramova, Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology of the Institute of Professional Education, Head of the Research and Outpatient Department, Obstetrician-Gynecologist, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparina str., 4;Professor at the Department of Obstetrics, Gynecology, Perinatology, and Reproductology of the Institute of Professional Education, I.M. Sechenov First MSMU,
Ministry of Health of Russia, 119991, Russia, Moscow, Trubetskaya str., 8-2, bayramova@mail.ru, https://orcid.org/0000-0003-4826-661X
Alexander O. Andreev, PhD, Researcher at the Research and Outpatient Department, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparina str., 4, sasha.grash2010@yandex.ru, https://orcid.org/0000-0002-9835-440X
Elena A. Mezhevitinova, Dr. Med. Sci., Leading Researcher at the Research and Outpatient Department, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia,
117997, Russia, Moscow, Ac. Oparina str., 4, mejevitinova@mail.ru, https://dx.doi.org/0000-0003-2977-9065
Patimat R. Abakarova, PhD, Senior Researcher at the Research and Outpatient Department, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparina str., 4, abakarova2002@mail.ru, https://orcid.org/0000-0002-8243-5272
Violetta D. Babich, PhD Student, Research and Outpatient Department, V.I. Kulakov NMRC for OG&P, Ministry of Health of Russia, 117997, Russia, Moscow,
Ac. Oparina str., 4, violettadmitrievna9@mail.ru, https://dx.doi.org/0009-0006-4101-0020
Similar Articles
